FIGURE 2.

RMD+IBET151 increases protein-elicited T cell responses in an accelerated prime-boost regimen, conferring superior CD8⁺ T cell–mediated melanoma protection. (A–D) C57BL/6 mice were vaccinated s.c. with OVA protein adjuvanted with CpG in combination with RMD+IBET151 or PBS/DMSO vehicle control. (A) Frequency of OVA-specific CD8⁺ T cells in the blood. (B) Experimental outline of B16-OVA challenge. Tumor area measurements and survival curves following B16-OVA tumor injection into vaccinated mice (C) and CD8⁺ T cell–depleted vaccinated mice (D). Each dot represents an individual mouse. n = 6–10 per group per experiment. Data are presented as means ± SEM. **p < 0.01, ***p < 0.001, Student t test.